Bristol and Regeneron sign separate cell therapy technology pacts, plus deals involving Takeda/ImmunoGen, Serina/AgeX, Cybin/Small Pharma, Taiho/Phost’in, Royalty/Ferring and Aardvark/GRI Bio.

Tricky drug development challenges have held back the NLRP3 inhibitor field for decades but Ventus and its many rivals believe the class can deliver on its huge potential, from Parkinson’s disease to NASH and arthritis.

The 19 breakthrough therapy designations awarded so far this year run the gamut from areas that traditionally have not fared well with BTDs, like cardiovascular and respiratory disease, alongside the traditional cancer and orphan disease tentpoles.

NodThera is a pioneer in the field of NLRP3 inflammasome inhibitors, and after overcoming drug development setbacks, believes it can compete in a field alongside rivals such as Roche, Novartis and Novo Nordisk.